NK cells, for instance, have been shown to destroy breast cancer cells by ADCC when the therapeutic antibody trastuzumab binds to the tumor cells’ surface epidermal growth factor receptor HER2 [18]. This evidence concerns the gene ERBB2 and breast carcinoma.